molecules Review s-Triazine: A Privileged Structure for Drug Discovery and Bioconjugation Anamika Sharma 1,2 , Rotimi Sheyi 1, Beatriz G. de la Torre 1,2 , Ayman El-Faham 3,4,* and Fernando Albericio 1,3,5,6,* 1 Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa;
[email protected] (A.S.);
[email protected] (R.S.);
[email protected] (B.G.d.l.T.) 2 KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa 3 Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia 4 Chemistry Department, Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia, Alexandria 12321, Egypt 5 Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain 6 CIBER-BBN (Networking Centre on Bioengineering, Biomaterials and Nanomedicine) and Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain * Correspondence:
[email protected] (A.E.-F.);
[email protected] (F.A.) Abstract: This review provides an overview of the broad applicability of s-triazine. Our many years working with this intriguing moiety allow us to discuss its wide activity spectrum (inhibition against MAO-A and -B, anticancer/antiproliferative and antimicrobial activity, antibacterial activity against MDR clinical isolates, antileishmanial agent, and use as drug nano delivery system). Most Citation: Sharma, A.; Sheyi, R.; of the compounds addressed in our studies and those performed by other groups contain only de la Torre, B.G.; El-Faham, A.; N-substitution.